文献速递类风湿关节炎

瑞典注册研究:达标持续缓解,生物制剂与三联疗法比较

Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
PubMed 文献 · Arthritis Rheumatol · 2021-05-10

基于瑞典风湿病质量注册2000-2012年数据,纳入MTX单药后首次升级治疗的1502例RA患者,比较生物制剂联合MTX与三联疗法(MTX+柳氮磺吡啶+羟氯喹/氯喹)的持续缓解效果。倾向评分校正后,开始治疗者生物制剂组短期及长期缓解的OR更高,但持续治疗者和任意随访时间的HR无显著差异。

要点

  • 开始治疗时生物制剂组1年短期缓解OR 1.79(95%CI 1.18-2.71),长期缓解OR 1.86(95%CI 1.00-3.48)。
  • 持续治疗者两组缓解概率相似,任意随访时间HR均无显著差异。
  • 对部分RA患者,三联疗法仍可作为生物制剂的替代而不影响未来持续缓解机会。

核心结论

  • 开始生物制剂或三联治疗时,生物制剂更有利于留在治疗和获得持续缓解。
  • 但在持续治疗患者中及任意随访时间,两组获得持续缓解的概率相似。
  • 对特定RA患者,三联疗法仍可能是生物制剂的替代选择而不妨碍未来持续缓解机会。

研究设计与样本

  • 瑞典全国风湿病质量注册(2000-2012年)的注册研究。
  • 纳入MTX单药后首次接受生物制剂(生物制剂DMARD+MTX)或三联疗法(MTX+柳氮磺吡啶+羟氯喹/氯喹)的RA患者。
  • 共纳入1502例患者,其中生物制剂组1155例,三联疗法组347例。
  • 采用倾向评分校正回归分析比较开始治疗和持续治疗患者,并用生存分析比较任意随访时间。
  • 持续缓解定义为DAS28<2.6持续≥6个月(短期)或≥24个月(长期)。

主要发现

  • 开始治疗者1年短期缓解OR 1.79(95%CI 1.18-2.71),长期缓解OR 1.86(95%CI 1.00-3.48)。
  • 开始治疗者2年短期缓解OR 1.92(95%CI 1.21-3.06),长期缓解OR 1.62(95%CI 0.94-2.79)。
  • 持续治疗者1年短期缓解OR 1.12(95%CI 0.72-1.75),长期缓解OR 1.1(95%CI 0.59-2.16)。
  • 持续治疗者2年短期缓解OR 0.85(95%CI 0.49-1.47),长期缓解OR 0.76(95%CI 0.41-1.39)。
  • 任意随访时间短期缓解HR 1.15(95%CI 0.91-1.46),长期缓解HR 1.09(95%CI 0.77-1.54)。

关键数值与推荐

  • 持续缓解定义为DAS28<2.6持续≥6个月(短期)或≥24个月(长期)。
  • 比较在治疗期间、1年、2年进行,并区分开始治疗与持续治疗患者。

临床怎么用

  • 开始治疗时生物制剂获得持续缓解的可能性更高,可优先考虑。
  • 对部分RA患者,三联疗法仍可作为生物制剂的替代,不影响未来持续缓解机会。
  • 持续治疗过程中两组缓解概率相似,治疗选择需结合患者具体情况。

局限性

  • 观察性注册研究,可能存在未测量混杂。
  • 三联疗法组样本量较小(347例),部分估计值置信区间较宽。
  • 结论基于瑞典注册数据,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the real-life effectiveness of biologic therapy (a biologic disease-modifying antirheumatic drug plus methotrexate [MTX]) versus triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) for sustained remission of rheumatoid arthritis (RA). METHODS: RA patients who were registered in the nationwide Swedish Rheumatology Quality Register between 2000 and 2012 and were receiving biologic or triple therapy as a first treatment strategy after MTX monotherapy were included. Sustained remission was defined as a Disease Activity Score in 28 joints (DAS28) of <2.6 for ≥6 months (short-term sustained remission) or for ≥24 months (long-term sustained remission). Treatment groups were compared during treatment, at 1 year, and at 2 years for 1) all patients starting therapy and 2) patients continuing to receive therapy, using propensity score-adjusted regression analyses. In addition, survival analyses were used to compare treatment groups at any time during follow-up irrespective of therapy retention. RESULTS: A total of 1,502 patients were included (1,155 receiving biologic therapy and 347 receiving triple therapy). For patients starting therapy, the adjusted odds ratios (ORs) of achieving short-term and long-term remission, respectively, at 1 year after start of biologic therapy versus triple therapy were 1.79 (95% confidence interval [95% CI] 1.18-2.71) and 1.86 (95% CI 1.00-3.48). At 2 years, the ORs were 1.92 (95% CI 1.21-3.06) and 1.62 (95% CI 0.94-2.79), respectively. For patients continuing to receive therapy, corresponding results at 1 year were 1.12 (95% CI 0.72-1.75) and 1.1 (95% CI 0.59-2.16); at 2 years, 0.85 (95% CI 0.49-1.47) and 0.76 (95% CI 0.41-1.39). Hazard ratios for short-term and long-term sustained remission at any time during follow-up were 1.15 (95% CI 0.91-1.46) and 1.09 (95% CI 0.77-1.54), respectively. CONCLUSION: Among patients starting biologic or triple therapy, biologic therapy was more effective for remaining on therapy and achieving sustained remission. However, similar probabilities were found for achieving sustained remission among patients remaining on therapy and at any time during follow-up irrespective of therapy retention. Although the likelihood of reaching sustained remission is higher with biologic therapy, for certain RA patients triple therapy may still be an alternative to biologic therapy without hampering future chances of obtaining sustained remission.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Källmark H, Einarsson JT, Nilsson JÅ, et al. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study. Arthritis Rheumatol. 2021. PMID: 33682353. doi:10.1002/art.41720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。